A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Exploratory Study to Evaluate Effects of VX-661 in Combination With Ivacaftor on Lung and Extrapulmonary Systems in Subjects Aged 18 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 08 Aug 2017 Status changed from recruiting to completed.
- 23 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jul 2017.
- 23 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2017.